Exercise Performance on Ambient Air vs. Commonly Prescribed Nasal Low Flow Oxygen Therapy in Patients With Exercise Induced Desaturation Due to Pulmonary Disease
| Registry | NCT07777367 |
|---|---|
| Status | Recruiting |
| Phase | Not applicable |
| Study type | Interventional; randomized, crossover, masking: none, other |
| Enrollment | 40 (Estimated) |
| Sponsor | Silvia Ulrich Somaini (Other) |
| Conditions | Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Arterial Hypertension (PAH) |
| Interventions | 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX) (Other) |
| Dates | start 2026-10-01 (estimated), primary completion 2028-12-31 (estimated), completion 2028-12-31 (estimated), first posted 2026-08-20, last updated 2026-09-09 |
| Locations | 1 site in Switzerland |
Related Papers Related Patents Related Grants Related Experts
All trials for Pulmonary Vascular Disease All trials for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) All trials of 6-minute walk distance (6MWD) test on ambient conditions All trials of 6-minute walk distance (6MWD) test with supplemental oxygen (LOX)
The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
Participants with PVD diagnosed with precapillary PH with right heart catheterization and classified to groups 1 and 4 (PAH or CTEPH) who live in Switzerland will have 6-minute walk distance (6MWD) test with and without nasal liquid oxygen therapy (LOX) approximately 4l/min via nasal cannula according to a randomized cross-over design.
The trial aims to test that the 6MWD with LOX is inferior to a 6MWD in the same participant under ambient air.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Ambient air | Experimental | Other: 6-minute walk distance (6MWD) test on ambient conditions | Patient will be assessed at University Hospital Zurich |
| Liquid oxygen therapy via nasal canula | Active comparator | Other: 6-minute walk distance (6MWD) test with supplemental oxygen (LOX) | Supplemental Liquid Oxygen Therapy (LOX) at approximately 4l/min will be provided via nasal canula from a small oxygen tank at University Hospital Zurich to perform clinical assessments. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Minimum 18 years of age * Written informed consent * Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease * Former desaturation under exercise defined as SpO2-decrease >3% * Treated with a stable drug therapy (with no changes for at least 14 days prior to screening) Exclusion Criteria: * Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 < 6.9 kPa * Inability or contraindications to undergo the investigated intervention * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.
| Facility | City | Country | Status |
|---|---|---|---|
| University Hospital Zurich | Zurich, Canton of Zurich | Switzerland | Recruiting |